Taysha Gene Therapies (TSHA) Projected to Post Quarterly Earnings on Wednesday

Taysha Gene Therapies (NASDAQ:TSHA) is anticipated to post its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 9:30 AM ET.

Taysha Gene Therapies Stock Up 0.7%

NASDAQ:TSHA opened at $4.58 on Wednesday. The company’s 50-day simple moving average is $5.07 and its 200-day simple moving average is $4.29. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.48 and a current ratio of 10.48. Taysha Gene Therapies has a fifty-two week low of $1.05 and a fifty-two week high of $6.02. The stock has a market capitalization of $1.25 billion, a P/E ratio of -13.88 and a beta of 1.01.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on TSHA shares. Citigroup reissued an “outperform” rating on shares of Taysha Gene Therapies in a research report on Wednesday, November 5th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 target price on shares of Taysha Gene Therapies in a research note on Friday, November 14th. Citizens Jmp set a $8.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. UBS Group set a $11.00 price target on shares of Taysha Gene Therapies in a report on Thursday, December 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.91.

Insider Buying and Selling

In other news, CEO Sean P. Nolan sold 41,312 shares of the firm’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $190,448.32. Following the transaction, the chief executive officer owned 2,908,257 shares in the company, valued at $13,407,064.77. This trade represents a 1.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Kamran Alam sold 23,849 shares of the business’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $109,943.89. Following the sale, the chief financial officer owned 1,443,786 shares of the company’s stock, valued at $6,655,853.46. The trade was a 1.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 968,795 shares of company stock worth $4,518,093. Insiders own 3.78% of the company’s stock.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. grew its position in shares of Taysha Gene Therapies by 2.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 13,692,739 shares of the company’s stock valued at $75,310,000 after purchasing an additional 309,031 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Taysha Gene Therapies by 17.9% during the 3rd quarter. Vanguard Group Inc. now owns 12,849,613 shares of the company’s stock worth $42,018,000 after acquiring an additional 1,955,486 shares during the period. Octagon Capital Advisors LP boosted its position in shares of Taysha Gene Therapies by 17.7% during the 2nd quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock valued at $29,089,000 after acquiring an additional 1,892,500 shares during the last quarter. State Street Corp grew its holdings in shares of Taysha Gene Therapies by 49.1% in the fourth quarter. State Street Corp now owns 10,790,084 shares of the company’s stock valued at $59,345,000 after purchasing an additional 3,553,619 shares during the period. Finally, Barclays PLC raised its stake in Taysha Gene Therapies by 7.6% during the fourth quarter. Barclays PLC now owns 5,539,001 shares of the company’s stock worth $30,465,000 after purchasing an additional 390,889 shares during the period. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.